Belotero Intense (+) Lidocaine
Merz North America, Inc. · Decision date Jul 9, 2026
What did the FDA approve?
FDA records P250016 as an original PMA application. The recorded decision is approval, dated Jul 9, 2026.
FDA approval order statement
Belotero Intense (+) Lidocaine is indicated for submucosal and/or subcutaneous implantation for lip augmentation in adults over the age of 21.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jul 9, 2026
Regulatory record facts
- Identifier
- P250016
- Regulatory pathway
- Premarket approval application
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Jul 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250016 received
Application receipt date recorded by FDA.
P250016 · FDA decision
APPR
P250016/S006 · Related supplement
Belotero Intense (+) Lidocaine Dermal Filler
Timeline entries are records held by MedtechLedger for P250016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Merz North America, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6501 Six Forks Rd., Raleigh, NC, 27615
Sources and methodology
- Original FDA record: P250016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



